Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown to help with weight loss and maintain the lost weight in clinical trials when combined with diet and exercise. It is a once-weekly injection that can be self-administered and should be used alongside dietary changes and exercise.
Mounjaro works by activating two gut hormone receptors, GIP and GLP-1, to manage blood sugar. This stimulates insulin release when glucose is high, reduces liver glucagon production, slows stomach emptying to control post-meal sugar spikes, and increases fullness to reduce appetite and food intake.
Mounjaro’s dual mechanism of action makes it significantly more effective than semaglutide for weight loss, which only activates GLP-1 receptors, as demonstrated in the head-to-head Surmount-5clinical trial (NCT05822830), which reported an overall 47% greater weight loss with tirzepatide (Mounjaro, Zepbound) compared to semaglutide.
- Weight loss: 20.2% with tirzepatide vs.13.7% with semaglutide
- Average weight loss: 50.3 lbs with tirzepatide vs. 33.1 lbs with semaglutide
- Waist circumference reduction: 7.2 inches with tirzepatide vs. 5.1 inches with semaglutide.
Mounjaro (tirzepatide) received FDA approval on May 13, 2022. There is no Mounjaro generic. The 2 different brands of tirzepatide (Mounjaro and Zepbound) are made by Eli Lilly and Company but are FDA-approved for different conditions.
- Mounjaro: Specifically approved for type 2 diabetes management in adults.
- Zepbound: Designated for weight losstreatment in adults.
Reviews
There are no reviews yet.